Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Carcinoma 1

Interventions

pembrolizumab 7Cisplatin 7Magnetic Resonance Spectroscopy 6Specimen Handling 5Radiotherapy, Intensity-Modulated 4Carboplatin 4Taxes 3Radiotherapy 3Platinum 3Paclitaxel 31,2-diaminocyclohexaneplatinum II citrate 3durvalumab 2Optical Imaging 2Nivolumab 2Biopsy 2peposertib 1niraparib 1nabiximols 1ipatasertib 1dostarlimab 1dehydroftorafur 1cemiplimab 1atezolizumab 1X-Rays 1Tretinoin 1Surveys and Questionnaires 1Spectrometry, Fluorescence 1Radiosurgery 1Radiation 1Proflavine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Mouth Neoplasms × peposertib × Clear all
NCT04533750 2026-04-13

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 1 Active not recruiting
21 enrolled
Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡